Clinical and biochemical effects of a combination botanical product (ClearGuard™) for allergy: a pilot randomized double-blind placebo-controlled trial by Corren, Jonathan et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Nutrition Journal
Open Access Research
Clinical and biochemical effects of a combination botanical product 
(ClearGuard™) for allergy: a pilot randomized double-blind 
placebo-controlled trial
Jonathan Corren1, Marc Lemay*2, Yumei Lin2, Lisa Rozga2 and R 
Keith Randolph3
Address: 1Allergy Research Foundation, Los Angeles, USA, 2Supplement Product Development, Nutrilite Health Institute, Buena Park, USA and 
3Analytical Services, Alticor Inc, Ada, USA
Email: Jonathan Corren - jcorren@ucla.edu; Marc Lemay* - marc.lemay@nutrilite.com; Yumei Lin - yumei.lin@nutrilite.com; 
Lisa Rozga - lisa.rozga@nutrilite.com; R Keith Randolph - keith.randolph@alticor.com
* Corresponding author    
Abstract
Background: Botanical products are frequently used for treatment of nasal allergy. Three of these
substances, Cinnamomum zeylanicum, Malpighia glabra, and Bidens pilosa, have been shown to have a
number of anti-allergic properties in-vitro. The current study was conducted to determine the
effects of these combined ingredients upon the nasal response to allergen challenge in patients with
seasonal allergic rhinitis.
Methods: Twenty subjects were randomized to receive the combination botanical product, (CBP)
2 tablets three times a day, loratadine, 10 mg once a day in the morning, or placebo, using a
randomized, double-blinded crossover design. Following 2 days of each treatment and during the
third day of treatment, subjects underwent a nasal allergen challenge (NAC), in which nasal
symptoms were assessed after each challenge dose and every 2 hours for 8 hours. Nasal lavage fluid
was assessed for tryptase, prostaglandin D2, and leukotriene E4 concentrations and inflammatory
cells.
Results: Loratadine significantly reduced the total nasal symptom score during the NAC compared
with placebo (P = 0.04) while the CBP did not. During the 8 hour period following NAC, loratadine
and the CBP both reduced NSS compared with placebo (P = 0.034 and P = 0.029, respectively).
Analysis of nasal lavage fluid demonstrated that the CBP prevented the increase in prostaglandin
D2 release following NAC, while neither loratadine nor placebo had this effect. None of the
treatments significantly affected tryptase or leukotriene E4 release or inflammatory cell infiltration.
Conclusion: The CBP significantly reduced NSS during the 8 hours following NAC and marginally
inhibited the release of prostaglandin D2 into nasal lavage fluid, suggesting potential clinical utility
in patients with allergic rhinitis.
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Background
Recent surveys conducted in the United States reveal that
a significant proportion of the population have utilized
botanical products for the treatment of nasal allergy
symptoms [1-3]. While many of these substances have
been widely used throughout the world, there have been
relatively few controlled clinical trials to support their use.
Several botanicals, including Spanish needles (Bidens
pilosa) [4,5] and cinnamon extract (Cinnamomum cas-
sia)[6] have been reported to have significant effects upon
a number of allergic processes, including but not limited
to the inhibition of histamine release and synthesis of
lipid-derived mediators. Based upon these prior data, a
number of candidate substances were screened for their
effects on basophil histamine release (data not shown).
The results of the histamine release experiments suggested
that three plant materials, including Spanish needles, cin-
namon (Cinnamomum zeylanicum), and acerola (Malpighia
glabra) might be most useful in inhibiting the acute effects
of allergen exposure. The purpose of the current study was
to determine the subjective (nasal symptoms) and objec-
tive (sneeze counts, peak expiratory flow, nasal lavage
inflammatory mediator bioassays) effects of a combina-
tion of Spanish needles powder, cinnamon extract, and
acerola extract, upon early and late-phase responses to
nasal allergen challenge, compared with an oral H1 anti-
histamine and placebo, in patients with seasonal allergic
rhinitis.
Methods
Study design
A randomized, double-blind, placebo-controlled, double-
dummy, crossover, single-center clinical study was
designed to assess the effivacy of ClearGuard™ (combina-
tion botanical product, CBP) for allergy symptoms. The
CBP is composed of equal parts by weight Cinnamon
(Cinnamomum zeylanicum) bark extract (4:1 ethanol and
water extract), acerola (Malphighia glabra) fruit concen-
trate (concentrated by filtration and dehydration to a ratio
of 1:9.5), and Spanish Needles (Bidens pilosa) leaf and
stem dehydrated powder (CBP; ClearGuard™, Access Busi-
ness Group LLC, Buena Park, CA). CBP treatment was 450
mg three times daily (given at approximately equal inter-
vals throughout the day). Other treatments were lorata-
dine (Claritin™)10 mg once a day in the morning; and
placebo, three times daily.
The CBP and loratadine were in tablet form. Two different
placebos were also provided to subjects, one in capsule
form and one in tablet form. Study products were pro-
vided in tear-pouches containing individual servings
labelled for order of consumption (first, second, or third
dose of the day). All subjects took a combination of tab-
lets and capsules at each dose, in a combination of active
product or placebo as necessary to maintain blinding. No
one having direct contact with the subjects had knowledge
of the identity of the products.
Each treatment involved 3 doses a day for 3 days, with the
third day of dosing occurring on the day of the nasal aller-
gen challenge (NAC). Each study treatment was separated
by a period of 3 to 7 days of no treatment and no nasal
allergen challenge. Over a period of about three weeks,
subjects were to be exposed to all three treatments in one
of the following sequences: CBP, loratadine, Placebo (CLP
sequence); loratadine, Placebo, and CBP (LPC sequence);
loratadine, CBP, Placebo (LCP sequence); or Placebo,
CBP, loratadine (PCL sequence). Random assignment to
treatment sequence was effected by means of a randomi-
zation list provided by the Sponsor. The list featured
twenty four-digit subject numbers in the first column, and
a sequence name ("Sequence 1" through "4") in the sec-
ond column. Subjects were sequentially assigned a subject
number with its associated sequence as they were
enrolled.
The study protocol was approved by Coast IRB (Colorado
Springs, CO) and was conducted in compliance with the
Declaration of Helskinki. Every subject gave signed
informed consent before any study procedures were initi-
ated. The study took place from July to August 2005 at the
Allergy Research Foundation, Los Angeles, California.
Subjects
Twenty adults, currently asymptomatic but with at least a
2 year history of seasonal allergic rhinitis during the
spring, summer and/or fall seasons were recruited for the
study. Subjects had to be non-smoking adults aged 18 to
65 years, and were required to have a positive skin prick
test (mean wheal diameter 3 mm greater than saline con-
trol) to a standardized extract of Timothy grass (100,000
AU/ml; Greer Labs, Lenoir, NC). Subjects also had to be
pollen or animal-dander allergy asymptomatic at the time
of the study, and in good general health as determined by
a medical exam and history, and standard serum bio-
chemistry, hematology, urinalysis. Exclusion criteria
included the current use of allergy relief medication; the
use of dietary supplements such as vitamins, minerals,
and herbals products or drinks within one week of the
start of the study; a clinically significant history or pres-
ence of cancer, cardiovascular disease, endocrine, kidney,
liver, lung, gastrointestinal, or metabolic disorder, any
other chronic health condition such as diabetes identified
from the findings of the interview. Subjects with nasal
pathology other than seasonal allergy that resulted in sig-
nificant nasal obstruction, with a recent history of viral
upper respiratory infection or sinusitis 6 weeks before the
study, or who drank greater than two alcoholic beverages
a day on average were excluded, as were subjects who had
participated in another clinical trial within 30 days ofNutrition Journal 2008, 7:20 http://www.nutritionj.com/content/7/1/20
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enrollment into the study, pregnant or lactating women,
or women of child-bearing potential unwilling to use a
medically approved form of birth control.
Nasal Allergen Challenge
The nasal allergen challenge (NAC) procedure was per-
formed using a spray bottle delivering 0.07 ml per spray.
Diluent (NaCl, 0.9%, albumin, 0.3%), 2 sprays per nos-
tril, was administered initially, followed by increasing
concentration of allergen extract (50, 250, 1250 and 6250
AU/ml), 2 sprays per nostril, given every 10 minutes. Both
nostrils were sprayed at each allergy concentration (two
sprays per nostril, for a total of four sprays per concentra-
tion). Not all subjects underwent the full dose-response
due to maximum possible response before reaching the
full dose (6250 AU/ml). Patients left the clinic after all
procedures were conducted during the NAC, and were not
allowed to use any symptomatic treatment over the next
24 hours.
Clinical assessments
Ten minutes after diluent and each dose of allergen, and
2, 4, 6 and 8 h after the completion of the NAC, patients
rated their nasal and ocular symptoms as follows: abso-
lute sneeze count per two hour period; score on the Nasal
Symptom Scale, comprising the components sneezes (in
last two hours: 3 sneezes = 1, > 5 sneezes = 2); rhinorrhea
(anterior discharge = 1, postnasal drip = 1, both = 3); nasal
blockage (breathes freely = 0, breathes with difficulty = 1,
one nostril blocked = 2, both nostrils blocked = 3); pruri-
tis (nasal = 1, palate or ear = 1); conjunctivitis (any ocular
itch = 1). Nasal inspiratory peak flow was also measured
at all of the same time points, in triplicate, and the best
value was recorded.
Nasal lavage
Nasal lavage was performed by instilling and collecting 5
ml of buffered nasal saline per nostril prior to NAC, 10
minutes after the completion of NAC, and 24 hours later.
Prostaglandin D2, leukotriene E4, and tryptase were
measured in lavage fluid at each of the above time points.
Cell counts were performed on undiluted lavage fluid and
differential counts were performed on Wright stains of
lavage samples centrifuged at 4°C for 10 min at 400 g,
prior to and 24 hours after each nasal challenge.
Safety monitoring
Incidence and severity of adverse events, as well as any
changes from baseline in laboratory values including
complete blood count and differential, chemistry panel,
and urinalysis, were assessed at the end of each treatment
period.
Statistics
A sample size of 20 (all subjects exposed to all treatments
in a crossover design) provided 80% power at the alpha
level of 0.05 to detect a mean difference of 0.5 points on
the Nasal Symptoms Scale, which corresponds to the
smallest clinically meaningful difference in allergy treat-
ment on an composite scale like the NSS [7]. The primary
efficacy measure was change from baseline NSS scores at
each time point, as well as total NSS scores. Secondary
outcome measures included nasal inspiratory peak flow
rate, PGD2, leukotriene E4, tryptase, total cell count, and
percent eosinophils, which were assessed at both discrete
time points and using the average across time points dur-
ing the early (acute challenge) and late (hours 2–8)
phases comparing the 2 active treatments with placebo
using one-tailed paired t-tests. Results are expressed as
group means with standard errors of the means. An alpha
value of P < 0.05 following a paired t test was considered
significant. Due to the pilot nature of this study, no cor-
rections were made for multiple comparisons. All rand-
omized subjects were included in the intent-to-treat (ITT)
population. The ITT population was defined as all sub-
jects were took at least one dose of study product followed
by the NAC, and then at least one dose of another study
product followed by the NAC. The safety population
included all subjects who were randomized, took at least
one dose of study product, and who returned to provide
any safety follow-up evaluation (physical examination,
laboratory tests, subjective reports).
Results
Subjects
Twenty subjects (11 women) with a mean age of 38 years
gave their informed consent and were screened for partic-
ipation in this study. Seventeen subjects completed all
treatments (loratadine, CBP, placebo); 3 subjects who
were did not complete all test procedures were excluded
from pairwise analyses on a per-comparison basis (Table
1). Due to error during allocation to treatment sequences,
five subjects were given the CBP (C), Placebo (P) and
loratadine (L) treatments in sequences other than
intended, as follows [sequence: intended n/actual n]: CLP:
5/2; LPC: 5/4; LCP: 5/4; PCL: 5/4; PCL: 0/5.
Clinical response
Because some subjects reported the highest possible nasal
symptom scores at Allergen Units/ml lower than the max-
imum, not all subjects were exposed to the two highest
challenges. There were no treatment differences in the
number of subjects who were unable to tolerate the high-
est allergen challenges: Of 20 subjects per allergen dose,
all subjects were able to tolerate the 50 AU/ml and 250
AU/ml challenges; but for each treatment, four subjects
were not exposed to the 1250 AU/ml challenge, and five
subjects were not exposed to the 6250 AU/ml challenge.Nutrition Journal 2008, 7:20 http://www.nutritionj.com/content/7/1/20
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Total nasal symptom scores measured immediately after
each dose of allergen were significantly suppressed by
loratadine at the highest dose of allergen (6250 AU) (P =
0.04; Figure 1), as well as overall (P = 0.04; Figure 1, inset)
expressed as the sum of nasal symptoms experienced over
the NAC compared with placebo, while the CBP had no
effects on nasal symptoms at these time points.
During the 8 hour observation period following the NAC,
treatment with both the CBP and loratadine resulted in
significantly lower mean nasal symptom scores than pla-
cebo at the 6 hour time-point (P = 0.007 and 0.01, respec-
tively; Figure 2) and for hours 2–8 area-under-curve (P =
0.04 for both treatments; Figure 3) compared with pla-
cebo. The CBP and loratadine were not significantly dif-
ferent from each other at any time point or for the area-
under-curve analysis. There were no differences in peak
expiratory flow rates at any time with any treatment.
Compared with placebo, the CBP reduced sneezing at 6
hours (P = 0.04) (Figure 4) as well as for the AUC analysis
(P = 0.04), while loratadine led to significantly fewer
sneezes compared to placebo at 6 and 8 hours (P = 0.02
and 0.03) but not for the AUC analysis. Other individual
symptom scores were not significantly affected by either
active treatment (Table 2).
Analysis of nasal fluid mediators and inflammatory cells
Analysis of mediator concentrations in nasal lavage fluid
following NAC demonstrated that the CBP prevented the
rise in prostaglandin D2 from baseline levels (P = 0.62),
while neither placebo nor loratadine treatments blocked
these increases (P = 0.04 and 0.006 respectively; Figure 5).
However, there were no significant intergroup differences
for this parameter. Neither active treatment significantly
affected tryptase or leukotriene E4 release or inflamma-
tory cell infiltration (data not shown) compared to pla-
cebo.
Adverse events
Blood chemistries, hematology, and urinalysis were per-
formed before and after each three-day period of dosing.
Review of laboratory findings and subjective adverse event
reports revealed no untoward signs or symptoms associ-
ated with consumption of any of the products during
these three-day dosing periods.
Nasal Symptom Scale scores by time and treatment Figure 2
Nasal Symptom Scale scores by time and treatment. 
Results from an 8-hour period of at-home ratings by subjects 
following the laboratory-based Nasal Allergen Challenge. 
Because not all subjects underwent the full dose-response in 
the laboratory, the results above represent symptoms fol-
lowing a maximum dose of 250, 1250, or 6250 AU/ml from, 
respectively, 5, 2, and 13 subjects in the Placebo treatment 
condition; 6, 1, and 13 subjects in the loratadine treatment 
condition; and 4, 2, and 13 subjects in the CBP treatment 
condition.
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Nasal Symptom Scale scores by allergen challenge dose and  treatment Figure 1
Nasal Symptom Scale scores by allergen challenge 
dose and treatment. Not all subjects underwent the full 
dose-response due to maximum possible response before 
reaching the full dose (6250 AU/ml). The number of subjects 
tested at 0, 50, 250, 1250, and 6250 AU/ml were respectively 
20, 20, 20, 15, and 13 in the Placebo treatment condition; 20, 
20, 20, 14, and 13 in the loratadine treatment condition; and 
19, 19, 19, 15, and 13 in the CBP treatment condition.
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Table 1: Demographics of the study population
No. of subjects enrolled 20
No. of subjects completing all treatment conditions 16
Mean age (SD) (y) 38.2 (3.34)
Mean height (SD) (in) 64.7 (3.56)
Mean weight (SD) (lb) 153.5 (31.57)
Sex (%)
Male 45
Female 55Nutrition Journal 2008, 7:20 http://www.nutritionj.com/content/7/1/20
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Discussion
The objective of the current study was to determine the
effects of the botanical product, compared with placebo
and loratadine, upon the clinical and inflammatory
responses to nasal allergen provocation. We demon-
strated that the CBP significantly reduced nasal symptoms
during hours 2 through 8 following the challenge and
blocked the post-allergen rise in prostaglandin D2. Sub-
jectively, the magnitude of the difference between placebo
and the CBP was about 1.5 points on the 11-point Nasal
Symptoms Scale (NSS), which is greater than The smallest
clinically meaningful difference in allergy treatment
effects is about a 0.5 score step on an composite scale like
the NSS [7]. Thus, the clinical results with the CBP were
not only statistically significant but also clinically mean-
ingful, a conclusion also supported by the comparison to
loratadine, which was associated with symptom relief
greater than placebo but not significantly different from
the CBP.
Our study had limitations. In particular, the study popu-
lation was small, and without having any knowledge of
the pharmacokinetics of the botanical product, it is diffi-
cult to say whether a washout period of 3 to 7 days
between treatments was sufficient to prevent carry-over
effects. In addition, while our data indicate significant dif-
ferences between the experimental therapy and placebo, it
is important to note that these effects were statistically
assessed using one-tailed paired t-tests without correc-
tions for multiple comparisons, as befits the pilot nature
of this study. Finally, the generalizability of these labora-
tory-based results could be investigated in further labora-
tory-based or native disease studies.
While the combination was shown to have selected effects
upon allergic pathophysiology, we are unable to deter-
mine which of the three components contributed most to
these effects. Our choice of botanical substances for this
study was based upon prior in-vitro experiments which
demonstrated potentially beneficial effects with either the
individual components used in the CBP or phytochemi-
cals derived from these substances. A species of cinnamon
related to that found in the CBP, Cinnamomum cassia, has
been found to inhibit complement-dependent allergic
reaction by reducing immunological hemolysis, chemo-
tactic migration of neutrophils, and the generation of
chemotactic factors by mast cells in response to comple-
ment-activated serum [6]. Acerola contains vitamin C,
which has been shown to reduce concentrations of hista-
mine [8,9]. Spanish Needles (Bidens pilosa) has also been
found to have anti-allergic effects on mast cells and syn-
thesis of several inflammatory mediators [10]. Quercetin,
Change in nasal lavage fluid PGD2 concentrations after Nasal  Allergen Challenge Figure 5
Change in nasal lavage fluid PGD2 concentrations 
after Nasal Allergen Challenge.
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Nasal Symptom Scale scores Areas Under the Curve, 2–8 h  after Nasal Allergen Challenge Figure 3
Nasal Symptom Scale scores Areas Under the 
Curve, 2–8 h after Nasal Allergen Challenge.
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Sneezes per 2-hour period after Nasal Allergen Challenge Figure 4
Sneezes per 2-hour period after Nasal Allergen Chal-
lenge.
   





	




	





	
"$	$


Nutrition Journal 2008, 7:20 http://www.nutritionj.com/content/7/1/20
Page 6 of 8
(page number not for citation purposes)
Table 2: Nasal Symptom Scale scores and sneeze counts during late response phase
Comparison Measure Hours after 
Nasal Allergen
Challenge
Treatment Mean N SD t P (1-tailed)
Loratadine-
Placebo
Nasal
Symptoms
Score
2 Loratadine 5.1 18 3.5 -1.10 0.143
Placebo 5.9 18 3.1
4 Loratadine 4.1 18 3.4 -1.43 0.086 #
Placebo 5.1 18 3.1
6 Loratadine 3.2 18 2.8 -2.57 0.010 **
Placebo 4.4 18 3.6
8 Loratadine 3.1 18 2.6 -1.05 0.153
Placebo 3.8 18 3.4
AUC Loratadine 15.5 18 10.7 -1.82 0.044 *
Placebo 19.3 18 12.6
Sneeze count 2 Loratadine 2.2 17 3.0 -1.25 0.114
Placebo 3.8 17 5.5
4 Loratadine 2.6 17 4.0 -0.52 0.306
Placebo 3.2 17 4.5
6 Loratadine 1.4 17 2.3 -2.22 0.021 *
Placebo 3.6 17 5.8
8 Loratadine 1.2 17 1.6 -1.89 0.038 *
Placebo 2.7 17 3.8
AUC Loratadine 7.5 17 7.8 -1.79 0.047 *
Placebo 13.2 17 17.7
Placebo-CBP Nasal
Symptoms
Score
2 Placebo 5.8 17 3.1 1.39 0.091 #
CBP 4.7 17 2.3
4 Placebo 4.9 17 3.1 1.71 0.053 #
CBP 3.6 17 2.3
6 Placebo 4.2 17 3.5 2.74 0.007 **
CBP 2.4 17 2.4
8 Placebo 3.5 17 3.3 0.90 0.190
CBP 2.8 17 2.6
AUC Placebo 18.4 17 12.4 1.86 0.041 *
CBP 13.6 17 8.0
Sneeze count 2 Placebo 3.2 17 5.2 1.57 0.068 #
CBP 1.2 17 1.6
4 Placebo 2.7 17 4.4 1.72 0.052 #
CBP 1.2 17 1.9
6 Placebo 3.4 17 5.8 1.93 0.036 *
CBP 0.7 17 1.0
8 Placebo 2.3 17 3.7 0.90 0.191
CBP 1.5 17 2.3
AUC Placebo 11.5 17 17.2 1.76 0.049 *
CBP 4.6 17 3.9
Loratadine-
CBP
Nasal 
Symptoms 
Score
2 Loratadine 4.8 17 3.4 0.14 0.447
CBP 4.7 17 2.3
4 Loratadine 3.9 17 3.4 0.28 0.393
CBP 3.6 17 2.3
6 Loratadine 3.1 17 2.8 1.43 0.086 #
CBP 2.4 17 2.4
8 Loratadine 2.9 17 2.6 0.20 0.421
CBP 2.8 17 2.6
AUC Loratadine 14.7 17 10.5 0.51 0.308
CBP 13.6 17 8.0
Sneeze count 2 Loratadine 1.8 16 2.6 0.88 0.197
CBP 1.3 16 1.6Nutrition Journal 2008, 7:20 http://www.nutritionj.com/content/7/1/20
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a flavonoid found in Spanish Needles [11,12], has been
shown to stabilize mast cells and basophils, decrease leu-
kotriene synthesis and reduce the release of histamine and
other mediators [13]. Spanish Needles also contains ethyl
caffeate which has been shown in vitro to possess a variety
of anti-inflammatory effects [4,11]. Spanish Needles has
been shown to inhibit nuclear transcription factor kappaB
and its downstream inflammatory mediators in vitro [4,5].
The actual active ingredients are unknown, however,
which is typical for botanical products [14]. For example,
St-John's Wort, a single-ingredient botanical for depres-
sion which was once thought to possess a single active
molecule, is now known to possess several active constit-
uents [5], and its anti-depressant activity can only be
ascribed to the total extract, not to any specific molecule
or combination of molecules [15]. While this general state
of affairs accords well with the ancient concept of botani-
cal therapeutics, whereby the efficacy of any botanical –
and its possible advantage over a traditional single-com-
pound pharmaceutical – stems from its complex action
against multiple pharmacological targets [16], this poses
manufacturing and quality control challenges [17]. The
solution adopted by painstaking manufacturers in the
industry entails a combination of analytical techniques
and bioassays to ensure product standardization [18,19].
The manufacture of the present CBP involves testing for
the marker substances chlorogenic acid and cynarin for
the Spanish Needles powder, cinnamic acid for the cinna-
mon extract, and ascorbic acid for the acerola extract, all
verified by HPLC; as well as total polyphenols for the fin-
ished tablet, verified by UV/Vis spectroscopy. Microbio-
logical monitoring is also involved in quality control in
according with Good Manufacturing Practices.
While prior experiments using the individual components
or relevant isolated phytochemicals had particularly
prominent effects on histamine release and leukotriene
synthesis, in the current study the combination of the
three botanical products had no detectable effects on tryp-
tase or leukotriene C4 concentrations in nasal lavage fluid
nor any effect on the acute clinical response to allergen
challenge. A possible explanation for this discrepancy
between previous in vitro data and the current results in
allergic patients may relate to pharmacokinetic issues,
including the attainment of adequate tissue levels of the
active ingredients, or may reflect biologic differences
between basophil or animal mast cell systems and human
mucosal mast cells [20].
While the immediate, or early nasal response to allergen
provocation was not affected by the botanical prepara-
tion, we did note a significant reduction in nasal symptom
scores during the 8 hour time period following nasal chal-
lenge. The most likely explanation for this was the appar-
ent reduction in increased PGD2 secretion in the CBP-
treatment condition, compared to the loratadine- or Pla-
cebo-treatment conditions, noted immediately after aller-
gen exposure. To our knowledge, no prior studies have
examined the acute effects of PGD2 administration upon
nasal symptoms or function in humans. However, injec-
tion of PGD2 into the skin of nonallergic patients has
been shown to cause induration which lasted up to 6
hours [21]. In addition, one prior clinical trial in patients
with seasonal allergic rhinitis demonstrated that the addi-
tion of an oral cyclooxygenase-1 inhibitor (naproxyn
sodium) to a combination of oral H1-antihistamine plus
decongestant (chlorpheniramine plus pseudoephedrine)
augmented nasal symptom control significantly [22].
Both of these experimental findings suggest the role of
PGD2 in eliciting tissue inflammation and the potential
importance of blocking its effects in patients with allergic
nasal disease.
Consistent with our prior knowledge of these phytochem-
icals, no clinical or laboratory adverse events were noted
during this short-term trial. Although toxicity is consid-
ered unlikely, longer-term studies with the botanical
product would help to clarify its place in the clinician's
armamentarium for treating patients with persistent
symptoms.
The medical speciality of allergy and immunology has
recently seen an increase in the use of complementary and
alternative medicine by both patients and physicians [2].
Rational and effective use of such therapies requires con-
trolled clinical trials to demonstrate safety and efficacy.
However, because of the multifarious nature of botanicals
compared to pure single pharmaceuticals, some adjust-
ments are required to principles of Good Clinical Practice
[14]. In the present study, these are centered on the iden-
4 Loratadine 2.4 16 4.0 1.09 0.145
CBP 1.3 16 1.9
6 Loratadine 1.3 16 2.4 1.07 0.151
CBP 0.7 16 1.0
8 Loratadine 1.1 16 1.5 -0.55 0.295
CBP 1.4 16 2.3
AUC Loratadine 6.6 16 7.1 1.18 0.128
CBP 4.7 16 4.1
# P < 0.10, * P < 0.05, ** P ≤ 0.01
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tity of the active ingredients in the CBP, which are
unknown.
Conclusion
In this study, a dietary supplement composed of three
botanical ingredients was shown to safe and effective in a
well-recognized model of anti-allergic action. Its symp-
tom-reduction action was comparable to the positive con-
trol treatment loratadine. The CBP reduced nasal
symptoms occurring 2 to 8 hours after nasal allergen chal-
lenge and attenuated increases in PGD2 collected from
nasal lavage fluid. These clinical attributes hold promise
as a potential therapy for allergic rhinitis.
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